Table 3.

Clinical significance of individual genetic mutations in multivariate analysis^*

		NRM		Relapse		PFS		OS
Oncogenic variant	n	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
TP53
No	73	1.00		1.00		1.00		1.00
Yes	22	0.66 (0.14-3.00)	.59	2.59 (1.41-4.74)	.002	2.18 (1.25-3.82)	.006	1.99 (1.14-3.49)	.02
JAK2
No	43	1.00		1.00		1.00		1.00
Yes	52	0.89 (0.37-2.15)	.79	0.93 (0.56-1.56)	.79	0.90 (0.57-1.41)	.63	0.75 (0.47-1.19)	.22
ASXL1
No	74	1.00		1.00		1.00		1.00
Yes	21	1.69 (0.66-4.32)	.27	0.94 (0.51-1.74)	.84	1.08 (0.62-1.88)	.78	1.42 (0.85-2.38)	.18
TET2
No	77	1.00		1.00		1.00		1.00
Yes	18	0.80 (0.26-2.43)	.69	0.81 (0.41-1.60)	.54	0.91 (0.50-1.66)	.77	0.63 (0.33-1.19)	.15
SRSF2
No	80	1.00		1.00		1.00		1.00
Yes	15	1.13 (0.41-3.16)	.81	0.68 (0.32-1.45)	.32	0.75 (0.39-1.42)	.37	0.95 (0.50-1.79)	.87
DNMT3A
No	82	1.00		1.00		1.00		1.00
Yes	13	1.31 (0.35-4.93)	.69	1.04 (0.48-2.23)	.92	0.85 (0.43-1.69)	.65	1.22(0.63-2.33)	.56
RUNX1
No	82	1.00		1.00		1.00		1.00
Yes	13	0.74 (0.20-2.71)	.64	0.65 (0.31-1.39)	.27	0.64 (0.32-1.29)	.21	0.71 (0.37-1.37)	.31
CALR
No	83	1.00		1.00		1.00		1.00
Yes	12	0.63 (0.08-4.90)	.66	1.49 (0.75-2.98)	.26	1.19 (0.60-2.35)	.62	1.00 (0.52-1.94)	1.00
SF3B1
No	85	1.00		1.00		1.00		1.00
Yes	10	1.56 (0.50-4.86)	.44	0.73 (0.29-1.84)	.50	0.92 (0.44-1.93)	.83	0.96 (0.46-1.99)	.90
No. of gene mutations*	—	—		1.02 (0.83-1.24)	.88	1.02 (0.85-1.22)	.82	1.04 (0.87-1.25)	.64

Each gene present in ≥10 patients was individually tested in multivariate analysis with the factors listed in the Appendix.

^*Tested as continuous variable.